Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Africans Will Get Wider Access to Vaccines in New Distribution Deal

12/02/2021 | 03:06am EST

Vaccine-short Africa is hopeful of getting more COVID-19 doses, as a South African pharmaceutical firm is close to being the first in Africa to distribute them for sale across the continent.

U.S.-based Johnson & Johnson says it could soon grant a license to Aspen Pharmacare, Africa's biggest drugmaker, to produce an "African COVID-19 vaccine" called Aspenovax.

Aspen Pharmacare will not make its own vaccine but will package and sell the Johnson-produced vaccine as soon as early 2022. The company has a factory in South Africa from where it already distributes the Johnson & Johnson vaccine nationwide.

The proposed deal will significantly boost supplies in Africa, which has suffered serious shortages of vaccines, and is facing the spread of the new omicron variant.

The World Health Organization said only 3% of Africans are fully vaccinated.

Africa has been the focus of what African officials say is vaccine inequity, as Western countries prioritize distributing vaccines in their own nations. Boosters in the West far outnumber first vaccines in several southern African nations, statistics show.

"Africa's COVID-19 vaccination rates are significantly lower, compared to those seen in high-income countries, and we need to do something differently," said Adrian Thomas, Johnson & Johnson's vice president for global affairs.

The distribution deal with Aspen Pharmacare will provide for uniform access to Africans and equitable pricing, the companies said.

"Quite simply, without widespread vaccination and access to vaccines, this pandemic will not come to an equitable end," Thomas said.

"We are delivering on our commitment to make available 900 million doses of our COVID-19 vaccine to the African Union and the COVAX facility," he said. "Only by working together can we bring together the necessary skills, expertise and resources to support the vaccination of people who are in most need at this critical stage of the pandemic."

Stephen Saad, Aspen's CEO and founder, said the company is well-positioned because it is based in South Africa, already distributes the vaccine nationwide and is advocating for more vaccinations on the continent.

"If Aspen was not in Africa, would any of these doses have gone to the continent?" Saad asked. "I think not."

Strive Masiyiwa, head of the African Union's Africa Vaccine Acquisition Task Team, said the deal will make African nations less dependent on Western governments for vaccine supplies.

"It gives us flexibility," Masiyiwa said. "It gives us one of the key things we've called for: security of supply."

Copyright Voice of America. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

Stocks mentioned in the article
ChangeLast1st jan.
ASPEN PHARMACARE HOLDINGS LIMITED 0.49% 204 End-of-day quote.-9.11%
JOHNSON & JOHNSON 2.86% 167.63 Delayed Quote.-2.01%
All news about JOHNSON & JOHNSON
04:24pNvidia, General Electric fall; IBM, American Express rise
AQ
03:49pHealth Care Stocks Still Trying to Overcome Midday Slide
MT
02:14pUS Labor Department's OSHA Revokes COVID-19 Vaccination Order for Large Employers
MT
01:05pHealth Care Stocks Resisting Steeper Tuesday Market Losses
MT
11:44aGLOBAL MARKETS LIVE : Credit Suisse, Unilever, Nvidia, Tesla, American Express...
11:05aPrescription drugs, medical devices boost J&J in Q4
AQ
10:09aWALL STREET STOCK EXCHANGE : A roller-coaster week as Fed decision looms
10:02aJohnson & Johnson Posts Higher Fourth-Quarter Earnings; Sees COVID-19 Vaccine Sales of ..
MT
10:01aJohnson & Johnson Forecasts COVID-19 Vaccine Sales Of Up To $3.5 Billion In 2022
MT
09:06aHealth Care Stocks Flat to Lower During Pre-Bell Tuesday
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 304 M - -
Net income 2021 22 542 M - -
Net cash 2021 815 M - -
P/E ratio 2021 19,9x
Yield 2021 2,48%
Capitalization 441 B 441 B -
EV / Sales 2021 4,67x
EV / Sales 2022 4,39x
Nbr of Employees 134 500
Free-Float -
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 167,63 $
Average target price 182,83 $
Spread / Average Target 9,07%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Alex Gorsky Executive Chairman
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-2.01%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963
NOVO NORDISK A/S-17.16%210 749